These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 22454320)

  • 1. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.
    Büchel B; Rhyn P; Schürch S; Bühr C; Amstutz U; Largiadèr CR
    Biomed Chromatogr; 2013 Jan; 27(1):7-16. PubMed ID: 22454320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
    Zhou ZW; Wang GQ; Wan de S; Lu ZH; Chen YB; Li S; Chen G; Pan ZZ
    Chemotherapy; 2007; 53(2):127-31. PubMed ID: 17308379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
    Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
    J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Assay method for uracil, dihydrouracil, 5-fluorouracil and 5-fluoro-5, 6-dihydrouracil by high-performance liquid chromatography].
    Nakamura A; Kikuchi K; Ohishi T; Masuike T
    Gan To Kagaku Ryoho; 2004 Mar; 31(3):381-6. PubMed ID: 15045945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
    Ben Fredj R; Gross E; Ben Ahmed S; Hassine H; Saguem S
    Pathol Biol (Paris); 2009 Sep; 57(6):470-6. PubMed ID: 18619742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rapid HPLC-ESI-MS/MS method for determination of dihydrouracil/uracil ratio in plasma: evaluation of toxicity to 5-flurouracil in patients with gastrointestinal cancer.
    César IC; Cunha-Júnior GF; Duarte Byrro RM; Vaz Coelho LG; Pianetti GA
    Ther Drug Monit; 2012 Feb; 34(1):59-66. PubMed ID: 22210098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
    Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
    Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography-tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity.
    Serdar MA; Sertoğlu E; Uyanık M; Tapan S; Akın O; Cihan M
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):525-9. PubMed ID: 21107571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.
    Kosovec JE; Egorin MJ; Gjurich S; Beumer JH
    Rapid Commun Mass Spectrom; 2008; 22(2):224-30. PubMed ID: 18085512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity.
    Garg MB; Sevester JC; Sakoff JA; Ackland SP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Jul; 774(2):223-30. PubMed ID: 12076692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development, validation and application of a novel liquid chromatography tandem mass spectrometry assay measuring uracil, 5,6-dihydrouracil, 5-fluorouracil, 5,6-dihydro-5-fluorouracil, α-fluoro-β-ureidopropionic acid and α-fluoro-β-alanine in human plasma.
    Chavani O; Jensen BP; Strother RM; Florkowski CM; George PM
    J Pharm Biomed Anal; 2017 Aug; 142():125-135. PubMed ID: 28501750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy.
    Carlsson G; Odin E; Gustavsson B; Wettergren Y
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):757-63. PubMed ID: 25102934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.
    Vainchtein LD; Rosing H; Schellens JH; Beijnen JH
    Biomed Chromatogr; 2010 Apr; 24(4):374-86. PubMed ID: 19650151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.
    Gamelin E; Boisdron-Celle M; Guérin-Meyer V; Delva R; Lortholary A; Genevieve F; Larra F; Ifrah N; Robert J
    J Clin Oncol; 1999 Apr; 17(4):1105. PubMed ID: 10561167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.
    Wettergren Y; Carlsson G; Odin E; Gustavsson B
    Cancer; 2012 Jun; 118(11):2935-43. PubMed ID: 22020693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
    Peer CJ; McManus TJ; Hurwitz HI; Petros WP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Jun; 898():32-7. PubMed ID: 22565063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients.
    Kristensen MH; Pedersen P; Mejer J
    J Int Med Res; 2010; 38(4):1313-23. PubMed ID: 20926004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
    Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
    Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio.
    Sistonen J; Büchel B; Froehlich TK; Kummer D; Fontana S; Joerger M; van Kuilenburg AB; Largiadèr CR
    Pharmacogenomics; 2014 Sep; 15(13):1653-66. PubMed ID: 25410891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.